TP53 and cancer: Pharmacological inhibition of MDM2 for stabilization of p53 has been of interest for several years, particularly for cancers with MDM2 amplification, including liposarcoma, Ewing’s sarcoma, osteosarcoma, and leukemia (2, 10–12).